Innoviva Inc. Common Stock (INVA)

About INVA

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIA…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

159

Website

www.inva.com/

Fundamentals

1-day range

$20.8$21.07

Market cap

$1.53B

P/E (trailing)

4.21

P/E (forward)

9.49

EPS (trailing)

$4.05

Dividend yield

—

Beta

0.40

Avg. volume

790.8K

Ex-dividend date

September 8, 2015

Dividend pay date

September 30, 2015

Forecasts

4 analyst ratings

Innoviva Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.53BP/E 4.21
  $16.52$25.15
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.51BP/E 14.51
  $28.25$60.08
• AAPG

  Ascentage Pharma Group International American Depository Shares

  $18.28

  ▼ 2.16%
  Market cap $1.57BP/E —
  $30$91.5
• HROW

  Harrow Inc. Common Stock

  $37.23

  ▼ 3.40%
  Market cap $1.46BP/E —
  $28.54$54.85
• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.61BP/E —
  $14.72$49.91
• XNCR

  Xencor Inc. Common Stock

  $26.06

  ▼ 9.76%
  Market cap $1.44BP/E —
  $7.8$30.61
• MRVI

  Maravai LifeSciences Holdings Inc. Class A Common Stock

  $7.67

  ▼ 8.42%
  Market cap $1.66BP/E —
  $2.28$9.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• IHF: Healthcare Dashboard For August
  SeekingAlpha · 8/16/2026
• Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
  Yahoo · 8/11/2026
• How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
  Yahoo · 8/7/2026
• Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
  Benzinga · 8/7/2026
• Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
  SeekingAlpha · 8/6/2026
• Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
  Yahoo · 8/6/2026
• Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
  Yahoo · 8/5/2026
• Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
  Benzinga · 8/5/2026

• Stephen Basso · May 20, 2026 · Tax Withholding

  559 @ $22.24
• Pavel Raifeld · May 20, 2026 · Tax Withholding

  1.1K @ $22.24
• Marianne Zhen · May 20, 2026 · Tax Withholding

  1.1K @ $22.24
• Josephine Linden · May 18, 2026 · Grant

  9.2K
• Josephine Linden · May 18, 2026 · Grant

  9.5K
• Josephine Linden · May 18, 2026 · Grant

  5.7K
• Stephen Basso · May 15, 2026 · Grant

  1.1K
• Pavel Raifeld · May 15, 2026 · Grant

  1.1K
• Mark DiPaolo · May 4, 2026 · Grant

  10.0K
• Mark DiPaolo · May 4, 2026 · Grant

  9.8K
• Pavel Raifeld · May 4, 2026 · Grant

  312.5K
• Pavel Raifeld · May 4, 2026 · Grant

  126.6K
• Marianne Zhen · May 4, 2026 · Grant

  31.5K
• Marianne Zhen · May 4, 2026 · Grant

  12.8K
• Sarah J. Schlesinger · May 4, 2026 · Grant

  10.0K

Institutional Ownership

March 31, 2026

Total shares held

69.99M

Total value held

$1.61B

Institutional holders

277